]]>PathoQuest will be in attendance at 36th Annual JP Morgan Healthcare Conference being held in San Francisco on January 8 – 11, 2018. The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry which brings together global industry leaders, emerging fast-growth companies, innovative technology creators, globally minded service providers, and members of the investment community.

Contact us to arrange a meeting with PathoQuest Senior Management during the conference.

PathoQuest, a life sciences leader focused on improving pathogen identification in biological samples, today announced that it will conduct research with Mayo Clinic to study the company’s proprietary iDTECT Blood test. Mayo Clinic will explore the use of iDTECT Blood in the context of a prospective study designed to confirm the utility of a next generation sequencing-based metagenomic approach to identify pathogens in patients with neutropenic fever. PathoQuest will work with Robin Patel, M.D., Chair, Division of Clinical Microbiology and Director of the Infectious Disease Research Laboratory at the Mayo Clinic to conduct the study.

“We are delighted to work with Dr. Patel and Mayo Clinic to study the effects of iDTECT Blood in the diagnostic workup of immunocompromised patients suspected of infection,” said Helene Peyro-Saint-Paul, M.D., PathoQuest’s Chief Medical Officer. “Mayo Clinic’s experience with the use of metagenomic sequencing to identify pathogens responsible for infections aligns well with PathoQuest’s expertise in this field.”

Dr. Peyro-Saint Paul added: “Standard approaches like blood cultures often fail to identify a causative organism in patients with febrile neutropenia. The demonstrated ability of iDTECT Blood to improve the identification of bacteria and RNA and DNA viruses should lead to a more precise and rapid determination of the clinically relevant microorganisms.”

About PathoQuest

Greater Pathogen Detection for Better Decisions

PathoQuest, a spin out of Institut Pasteur, is a life sciences company offering a game changing metagenomics approach to improving pathogen detection in biological samples. PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform and a proprietary sample preparation process which is applicable to several types of samples with a proprietary pathogen genome sequence database and automated analysis pipeline. The company’s solution provides microbiologists and clinicians with a comprehensive analysis covering all known clinically relevant human pathogens.

PathoQuest has developed iDTECT Blood Test, the first and only clinical CE IVD metagenomic test in infectious disease. Using a single blood sample, the test provides clinicians and microbiologists with an improved method for detecting pathogens, particularly for immunocompromised patients with suspected infections. This new molecular diagnostic test should improve antibiotic stewardship and lead to better patient care through precision medicine.

Based on the company’s technological platform, PathoQuest also offers biopharmaceutical companies a disruptive approach to secure production of biologics like vaccines and recombinant proteins. PathoQuest’s solution is currently being utilized by several major biopharma companies for this purpose.

You are invited to our complimentary webinar entitled “Applying the Power of High Throughput Sequencing to Genetic Characterization of Biologics” on Friday, December 15, 2017 at 3PM CET (9AM EST) featuring presentations by Charles Hébert, PhD, PathoQuest’s Chief Technology and Information Officer.

High Throughput Sequencing (HTS) is now a well-established and wide-spread solution for genetic and genomic analysis. By providing information at nucleotide level, HTS opens new avenues for genetic characterization, cell lines clonality and genetic drift. We will present two applications of HTS, one on proviral insertion sites identification, and a second one on cell lines comparison by RNA-Seq. This webinar will provide real life examples of HTS and bioinformatics analysis and is of particular interest for analytical development leaders and QC managers.

Members of the Scientific Advisory Board are recognized infectious diseases, microbiology and next-generation sequencing experts. The Scientific Advisory Board will advise PathoQuest in its Research and Development efforts in metagenomics applied to infectious diseases diagnostics.

PathoQuest, a life sciences leader focused on improving pathogen identification in biological samples, today announced the creation of its Scientific Advisory Board (SAB) which includes the following five internationally recognized experts:

Marc Eloit, DVM, PhD, Institut Pasteur, PathoQuest founder, Professor of Virology and former head of the Virology Unit at the Veterinary School of Maisons-Alfort, France

“We are pleased to welcome these internationally renowned scientists and physicians to PathoQuest’s SAB,” said Pascale Beurdeley, PhD, PathoQuest’s Chief Scientific Officer. “Creating the SAB represents another important step forward for the company. Its members bring a wealth of experience across molecular testing and clinical infectious diseases which will be essential to guide us in prioritizing and driving forward our unique testing platform and clinical development programs.”

PathoQuest, a spin out of Institut Pasteur, is a life sciences company offering a game changing metagenomics approach to improving pathogen detection in biological samples. PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform and a proprietary sample preparation process which is applicable to several types of samples with a proprietary pathogen genome sequence database and automated analysis pipeline.

PathoQuest has developed iDTECT Blood Test, the first and only clinical CE IVD metagenomic test in infectious disease. Using a single blood sample, the test provides clinicians and microbiologists with an improved method for detecting and identifying pathogens, particularly for immunocompromised patients with suspected infections. This new molecular diagnostic test is designed with the objective to improve antibiotic stewardship and lead to better patient care through precision medicine.

Based on the company’s technological platform, PathoQuest also offers biopharmaceutical companies a disruptive approach to secure production of biologics like vaccines and recombinant proteins. PathoQuest’s solution is currently being utilized by several major biopharma companies.

PathoQuest, a life sciences leader focused on improving pathogen detection in biological samples, today announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center to establish the company’s proprietary iDTECT Blood test within MSK’s microbiology lab and to compare the test with standard testing methods utilized to identify microorganisms responsible for infections in patients presenting with febrile neutropenia. iDTECT Blood is the only CE-IVD NGS-based test which offers a culture-free, agnostic metagenomic approach to improving the breadth of pathogen detection. PathoQuest’s proprietary sample-to-report process provides microbiologists and clinicians an improved method for detecting bacteria and viruses in blood samples from immunocompromised patients with suspected infections.

“We are pleased to collaborate with Memorial Sloan Kettering, one of the leading cancer centers in the world, to further validate our iDTECT Blood test,” stated Jean-Francois Brepson, PathoQuest’s CEO. “This study will add to the clinical evidence we have accumulated to date which demonstrates the improved ability to identify bacteria and virus from blood samples using next-generation sequencing technology in combination with our proprietary iDTECT Blood sample preparation process and bioinformatics solution.”

“The identification of microorganisms in immunocompromised patients who present with a suspicion of infection represents a diagnostic challenge since standard microbiological testing methodologies are often not timely or effective,” stated Yi‐Wei Tang, M.D., Ph.D., Chief of the Clinical Microbiology Service at Memorial Sloan Kettering Cancer Center, and Professor of Pathology and Laboratory Medicine at the Weill Medical College of Cornell University. “This collaboration will enable the identification of bacteria and viruses responsible for infections and aligns with our mission to improve the quality of care for patients.”

About PathoQuest

Greater Pathogen Detection for Better Decisions

PathoQuest, a spin out of Institut Pasteur, is a life sciences company offering a game changing metagenomics approach to improving pathogen detection in biological samples. PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform and a proprietary sample preparation process which is applicable to several types of samples with a proprietary pathogen genome sequence database and automated analysis pipeline. The company’s solution provides microbiologists and clinicians with a comprehensive analysis covering all known clinically relevant human pathogens.

PathoQuest has developed iDTECT Blood Test, the first and only clinical CE IVD metagenomic test in infectious disease. Using a single blood sample, the test provides clinicians and microbiologists with an improved method for detecting pathogens, particularly for immunocompromised patients with suspected infections. This new molecular diagnostic test should improve antibiotic stewardship and lead to better patient care through precision medicine.

Based on the company’s technological platform, PathoQuest also offers biopharmaceutical companies a disruptive approach to secure production of biologics like vaccines and recombinant proteins. PathoQuest’s solution is currently being utilized by several major biopharma companies for this purpose.

]]>https://www.pathoquest.com/?feed=rss2&p=15980PathoQuest providing sponsorship for the IABS Conference on NGS for Adventitious virus detection in Biologics, October 26-27, Rockville, USA.https://www.pathoquest.com/?p=1568
https://www.pathoquest.com/?p=1568#respondThu, 26 Oct 2017 10:02:25 +0000https://www.pathoquest.com/?p=1568PathoQuest is providing sponsorship for the IABS (international Alliance for Biological Standardization) Conference on Next Generation Sequencing for Adventitious Virus Detection in Biologics to be held at USP Pharmacopeia, Rockville, Maryland on October 26-27, 2017. Professor Marc Eloit, viral safety expert for Pathoquest, will present new results of our collaborative study with LFB and Charles […]

]]>PathoQuest is providing sponsorship for the IABS (international Alliance for Biological Standardization) Conference on Next Generation Sequencing for Adventitious Virus Detection in Biologics to be held at USP Pharmacopeia, Rockville, Maryland on October 26-27, 2017. Professor Marc Eloit, viral safety expert for Pathoquest, will present new results of our collaborative study with LFB and Charles River Lab. Interested in learning more about PathoQuest’s NGS solution for bioproduction safety ? Contact us to arrange a meeting with Charles Hébert, Chief Technology and Information Officer and Jean-Marie Charpin, Ph.D., Global Commercial Head for Bioproduction Safety.

]]>https://www.pathoquest.com/?feed=rss2&p=15680PathoQuest providing sponsorship for the Second International Conference on Clinical Metagenomics (ICCMg2) – October 19-20, Genevahttps://www.pathoquest.com/?p=1524
https://www.pathoquest.com/?p=1524#respondThu, 19 Oct 2017 09:25:17 +0000https://www.pathoquest.com/?p=1524In addition to being a sponsor for the Second International Conference on Clinical Metagenomics (ICCMg) being held 19 and 20 October 2017 in Geneva, Switzerland, PathoQuest’s Chief Scientific Officer, Dr. Pascale Beurdeley, will be presenting on the company’s experience associated with the development of the CE-IVD Mark iDTECT Blood metagenomic test for pathogen detection on […]

]]>In addition to being a sponsor for the Second International Conference on Clinical Metagenomics (ICCMg) being held 19 and 20 October 2017 in Geneva, Switzerland, PathoQuest’s Chief Scientific Officer, Dr. Pascale Beurdeley, will be presenting on the company’s experience associated with the development of the CE-IVD Mark iDTECT Blood metagenomic test for pathogen detection on Thursday, 19 October at 14:30. For more information on her talk visit https://goo.gl/K9u7Zt.

In addition to the above, PathoQuest’s Chief Medical Officer, Dr. Hélène Peyro-Saint-Paul, and the company’s Chief Technology Information Officer, Dr. Charles Hébert, will also be attending the ICCMg. Contact us if you are interested in arranging a meeting with a member of the PathoQuest team in Geneva.

]]>https://www.pathoquest.com/?feed=rss2&p=15240PathoQuest to attend the 25th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), October 18-20, Berlin, Germany.https://www.pathoquest.com/?p=1502
https://www.pathoquest.com/?p=1502#respondWed, 18 Oct 2017 07:52:35 +0000https://www.pathoquest.com/?p=1502Interested in learning more about PathoQuest’s NGS solution for safety testing in association with cellular and gene therapy manufacturing ? Contact us to arrange a meeting with Jean-Marie Charpin, Ph.D., PathoQuest’s Global Commercial Head for Bioproduction Safety, during the upcoming 25th Annual Congress of the European Society of Gene and Cell therapy (ESGCT) being held on October 18-20 in Berlin, Germany.

]]>Interested in learning more about PathoQuest’s NGS solution for safety testing in association with cellular and gene therapy manufacturing ? Contact us to arrange a meeting with Jean-Marie Charpin, Ph.D., PathoQuest’s Global Commercial Head for Bioproduction Safety, during the upcoming 25th Annual Congress of the European Society of Gene and Cell therapy (ESGCT) being held on October 18-20 in Berlin, Germany.

]]>https://www.pathoquest.com/?feed=rss2&p=15020PathoQuest to present results from collaborative study on “Transcriptomic NGS for bioproduction safety” during Charles River Lab’s Viral Summithttps://www.pathoquest.com/?p=1474
https://www.pathoquest.com/?p=1474#respondMon, 09 Oct 2017 12:19:10 +0000https://www.pathoquest.com/?p=1474Dr Jean-Marie Charpin, Global Commercial Head for PathoQuest’s Bioproduction Safety business, will present validation data for a new NGS-based approach to detect viral transcripts in cells during the Charles River Lab Viral Summit being held on October 10th and 11th in San Mateo, California. The results of this collaborative study between PathoQuest, the LFB Group […]

]]>Dr Jean-Marie Charpin, Global Commercial Head for PathoQuest’s Bioproduction Safety business, will present validation data for a new NGS-based approach to detect viral transcripts in cells during the Charles River Lab Viral Summit being held on October 10th and 11th in San Mateo, California. The results of this collaborative study between PathoQuest, the LFB Group and Charles River Laboratories pave the way for the use of NGS to support viral safety testing for biologics. PathoQuest will also be presenting data at the meeting on the company’s bioinformatic pipeline dedicated to bioproduction safety.